The MRC PPU's collaboration with the pharmaceutical industry has won a prestigious Queen's Anniversary Prize for Higher Education.
The award recognises the work of the Division of Signal Transduction Therapy (DSTT) - a unique consortium bringing together the research expertise of 12 research teams, 8 in the MRC PPU and 4 in the School of Life Sciences at Dundee. The collaboration with AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck & Co, Merck KGaA and Pfizer helps to accelerate the development of new drugs to combat major diseases including cancer and diabetes.
The announcement was made on 17 November 2005 by Founder and Chairman of the Royal Anniversary Trust Mr Robin Gill CVO at a ceremony at St James's Palace attended by DSTT Co-directors Philip Cohen (MRC PPU) and Peter Downes (SLS) and Sir Alan Langlands, Principal of the University of Dundee.
Alan Langlands said: 'We are honoured that the work of our life scientists in this important area has been recognised with such a prestigious award. The DSTT is a unique, extraordinary and highly successful operation which is enabling the discovery of new drugs to treat major global diseases. It is a great tribute to the drive and vision of Philip Cohen, Peter Downes and other leading scientists, that the DSTT has gone from strength to strength in spite of the complexities, not only of the science, but of the international business environment in which it operates.'
Secretary of State for Education and Skills, Ruth Kelly said, 'I would like to congratulate the winners of The Queen's Anniversary Prizes for Higher and Further Education. The breadth of their achievement is an outstanding testament to the remarkable work being done by universities and colleges in the UK. They clearly demonstrate that we can be proud of our educational institutions and of the expertise and commitment to excellence of those who teach in them.'
The award will be made by the Queen at Buckingham Palace on February 16th 2006.
The award recognises the work of the Division of Signal Transduction Therapy (DSTT) - a unique consortium bringing together the research expertise of 12 research teams, 8 in the MRC PPU and 4 in the School of Life Sciences at Dundee. The collaboration with AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck & Co, Merck KGaA and Pfizer helps to accelerate the development of new drugs to combat major diseases including cancer and diabetes.
The announcement was made on 17 November 2005 by Founder and Chairman of the Royal Anniversary Trust Mr Robin Gill CVO at a ceremony at St James's Palace attended by DSTT Co-directors Philip Cohen (MRC PPU) and Peter Downes (SLS) and Sir Alan Langlands, Principal of the University of Dundee.
Alan Langlands said: 'We are honoured that the work of our life scientists in this important area has been recognised with such a prestigious award. The DSTT is a unique, extraordinary and highly successful operation which is enabling the discovery of new drugs to treat major global diseases. It is a great tribute to the drive and vision of Philip Cohen, Peter Downes and other leading scientists, that the DSTT has gone from strength to strength in spite of the complexities, not only of the science, but of the international business environment in which it operates.'
Secretary of State for Education and Skills, Ruth Kelly said, 'I would like to congratulate the winners of The Queen's Anniversary Prizes for Higher and Further Education. The breadth of their achievement is an outstanding testament to the remarkable work being done by universities and colleges in the UK. They clearly demonstrate that we can be proud of our educational institutions and of the expertise and commitment to excellence of those who teach in them.'
The award will be made by the Queen at Buckingham Palace on February 16th 2006.